Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 12/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.51 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 4/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238681 | 1.00 | PDK2 (0.55) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL2144278 | 0.85 | PDK2 (0.55) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL31171938 | 0.84 | TGM2 (0.39) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL10116531 | 0.81 | TGM2 (0.41) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL31238639 | 0.78 | CYP1A2 (0.57) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL2265773 | 0.78 | CYP1A2 (0.57) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL18413652 | 0.78 | TGM2 (0.49) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL520415 | 0.77 | PDK2 (0.55) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL12072640 | 0.77 | PDK2 (0.55) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL3878508 | 0.77 | PDK2 (0.55) | PDK2PDK4PGRPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131893-B1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| US-8431567-B2 | Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | OXTR, AVPR2, AVPR1B | PDK2 1654/4885PDK4 2676/4885PGR 322/4885 |
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | OXTR, AVPR2, AVPR1B | PDK2 709/4885PDK4 1373/4885PGR 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.